Key Highlights
- Hims & Hers Health shares are trading up 5.97% today, building on last week's rebound.
- The rally comes ahead of the company's second-quarter earnings report, due after market close on August 10.
- Analysts expect revenue of approximately $692 million and an EPS loss of $0.07 for the quarter.
- The move coincides with a broader rotation into healthcare stocks and continued platform expansion.
What's Happening With Hims & Hers Stock Today?
Hims & Hers Health (NYSE:HIMS) shares are climbing further today as investors position ahead of the company's second-quarter earnings report, due after market close on August 10. The move builds on last week's rebound from a selloff tied to a Federal Trade Commission-related issue. Analysts currently expect revenue of approximately $692 million and an adjusted EPS loss of $0.07 for the quarter, with full-year 2026 revenue guidance previously raised to a range of $2.8 billion to $3 billion.
Hims & Hers Health is a multi-specialty telehealth platform founded in 2017 and headquartered in San Francisco, California, connecting consumers with licensed healthcare professionals for virtual consultations and ongoing care, delivering prescription medications alongside a broad range of over-the-counter products through its websites and mobile app.
Sector Rotation and Product Expansion
Today's gain also coincides with a broader rotation into healthcare stocks this week, with sector funds showing renewed interest across telehealth and consumer health names. Hims & Hers continues expanding its platform through recent product launches, including a new AI-native Hers app and smart scale for weight-loss members, aimed at deepening the company's consumer ecosystem ahead of the print.
Investors are also weighing intensifying GLP-1 competition, with the company navigating its pivot away from compounded GLP-1 products while facing branded drug competition from Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY), even as international revenue surged 969% year-over-year in the first quarter.
Conclusion
Hims & Hers Health shares are rising today as investors position ahead of next week's second-quarter earnings report, building on last week's rebound and continued platform expansion. With options markets implying a modest post-earnings move, the print will be closely watched for signs of how the company's pivot away from compounded GLP-1 products is progressing.
This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.






Please wait processing your request...